BioSpace News Archive

FDA

FDA Action Alert: Merck, Insmed and Antares Pharma

The U.S. Food and Drug Administration (FDA) has a few target action dates scheduled for this week, including one for Sunday, September 23, which was approved in late August.

September 21, 2018
·
3 min read
·
Mark Terry
Drug Development

Some Cancer Cells Hide From Immunotherapy Treatments, Study Finds

Some cancer cells have a remarkable and frightening sense of self-preservation to avoid immunotherapy treatments. That is the finding from a new study conducted by researchers at the Fred Hutchinson Cancer Research Center in Seattle.

September 21, 2018
·
3 min read
·
Alex Keown
Deals

Canon Medical System Corporation partners with ACT Genomics for Precision Cancer Medicine Service in Japan

Canon Medical System Corporation completed the acquisition of the majority shares of ACTmed

September 21, 2018
·
2 min read
Drug Development

Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with Previously Treated Non-Small Cell Lung Cancer at Annual Meeting of the Chinese Society of Clinical Oncology

Innovent Biologics, Inc. today presented clinical research data on cohort C at the 2018 Annual Meeting of Chinese Society of Clinical Oncology (CSCO).

September 21, 2018
·
5 min read
BioForest

LUNGevity to Present New Data from Its Patient Preference Study at 2018 World Conference on Lung Cancer

LUNGevity’s Project Transform captures what patients are seeking from their treatments

September 21, 2018
·
4 min read
BioForest

LUNGevity to Present Two Studies from Its Patient FoRCe Research Center at the 2018 World Conference on Lung Cancer

LUNGevity to present information about Attitudes Toward Re-Biopsy and a Patient Education Audit

September 21, 2018
·
5 min read
Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)

Ipsen announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults

September 21, 2018
·
11 min read
Business

SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623

SanBio Co., Ltd. has agreed to enter into an equity and business alliances

September 21, 2018
·
4 min read
Business

SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623

SanBio Co., Ltd. hereby announces that it has resolved to enter into an equity and business alliances

September 21, 2018
·
19 min read
BioForest

LUNGevity to Present Data from Study on Patient Empowerment at 2018 World Conference on Lung Cancer

Study illuminates obstacles to patients receiving education about their disease

September 21, 2018
·
4 min read